Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Rotflmao VRA slim balls
need news on vra
in ngl 0.065
Lots of promo on that one in Europe
Ya how many Institutions own NGL ?? they could drive it I guess
ngl get 5 mil in funding from government today trading at .06cents???
Whoopi did they give that money back to investors.LOL
Rumoured Speculation on there Alpha Natural Interferon
There working on cure or therapy for SARS.
VRA
Called them and they are working
on 2 projects at this min
What there are who knows
Stock holding good after
run-up on thursday & fri
on big volumes
vra needs the news
Interferon the only drug that helps in SARS
http://www.sunspot.net/news/health/bal-te.lab27apr27,0,2963979.story?coll=bal-health-headlines
At Fort Detrick, a race to treat SARS
Skilled in deadly agents, Army experts test drugs to control the new virus
--------------------------------------------------------------------------------
Also see
Related Articles
China closes venues to halt SARS spread
Apr 27, 2003
Outbreak a heavy strain on China tourism
Authorities shorten May Day observance
Apr 27, 2003
China's live-animal markets part of agency's SARS investigation
Vendors may have role in first reported illness
Apr 27, 2003
Beijing orders theaters closed as SARS cases surge to 1,000
Health minister blamed for bungling outbreak resigns amid criticism
Apr 27, 2003
In Depth
SARS outbreak
Video
SARS symptoms (61K; KRT) (QuickTime plug-in required)
SARS virus (57K; KRT) (QuickTime plug-in required)
SARS travel (47K; KRT) (QuickTime plug-in required)
Photo Gallery
SARS outbreak
On The Web
Warning from the Centers for Disease Control and Prevention
WHO: Cases by country
Related Articles
SARS questions and answers
In Depth
Medicine & Science coverage
New coverage from The Sun.
Related Articles
Seminars and events
Top Stories
Mapping out a plan for getting exercise on the road
Fitness Q&A
Finding the man behind the muscle
His physique graces magazines, novels
In Mosul, attention turns toward needs of hospital
But Iraqi doctors wary of U.S. medical officers
Kolata on fitness:
13 more die of SARS in Asia
Thousands quarantined; fatalities reach Philippines; Strict new measures in effect
By Erika Niedowski
Sun Staff
Originally published April 27, 2003
FREDERICK -- A few weeks ago their world was all bioterror. They were fighting smallpox and other infectious diseases that could threaten U.S. troops.
Today, the Army's top scientists may also be the best hope in the fight against an enemy that no one expected -- the deadly virus responsible for SARS.
"When the fire bell rings, you go down the pole. It's the right thing. It's a clear public health emergency," says Peter B. Jahrling, principal scientific adviser at the U.S. Army Medical Research Institute for Infectious Diseases.
In sealed labs in nondescript buildings, scientists on the grounds of Fort Detrick are used to handling the most dangerous agents. They routinely work with the Ebola virus wearing full-body biohazard suits. Two years ago, they opened an anthrax-laced letter mailed to a U.S. senator and conducted sophisticated tests on the powder inside.
Now, researchers at this heavily guarded base near the Catoctin Mountains are testing more than 2,000 drugs that might be effective against severe acute respiratory syndrome. The aggressive virus has sickened more than 4,600 people and killed at least 276 worldwide since November.
On Friday, the Fort Detrick scientists infected three monkeys with the SARS virus in hopes that it will help them learn more about how it attacks the body.
Normally, they study the potential threat to U.S. troops from disease and biowarfare. Jahrling said it was a "hard sell" to convince some of them a few weeks ago how important it was to shift gears, particularly in the middle of the war in Iraq.
"It's a bit of a balancing act," he said. "We are probably the best-equipped lab to get these answers in short order."
Scientists here have screened about 125 compounds since receiving a plastic foam box containing samples of the SARS virus from the Centers for Disease Control and Prevention last month.
"We're not trying to be too clever, because we don't know enough about the virus to be too clever," said John W. Huggins, chief of viral therapeutics in the institute's virology division and head of the 20-member SARS team.
Already, they have determined that one leading drug, ribavirin, used in combination with steroids on SARS patients in Toronto and Hong Kong, is not effective.
The only drug that has stopped the new coronavirus from replicating is interferon. But scientists fear that the dose required is too toxic to be safe.
Screening 800 drugs
In all, Fort Detrick will be screening more than 800 drugs on the market, including 40 anti-virals used to treat AIDS, herpes, hepatitis and influenza. Finding an effective treatment among that group would be the best-case scenario because the drug could be used immediately.
But none seems promising so far.
Scientists are planning to test at least another 1,500 drugs that are under development in laboratories.
The National Institute of Allergy and Infectious Diseases in Bethesda has been gathering them, primarily from pharmaceutical companies, and sending them to Fort Detrick.
Huggins believes that at best, researchers will find an existing drug that "sort of works." But in the end, he says, it may be necessary to develop an altogether new one.
At least one drug firm, AVI BioPharma of Portland, Ore., has been collaborating with outside labs to do just that. The company, which has worked with animal coronaviruses in the past, plans to send its new compound to the National Institutes of Health for further testing, a spokeswoman said.
Viruses are harder to defeat than bacteria, in part because they frequently mutate. The new virus believed to be behind the SARS outbreak consists of a single strand of RNA, which can make mistakes as it replicates.
"RNA viruses are, by their nature, very easily mutated," Jahrling explained.
Another culprit?
They may also recombine with other viruses. Jahrling thinks that scientists world-wide have been too quick to discount the possibility of a co-infection -- the coronavirus operating in concert with another agent.
Early on in the outbreak, researchers isolated a paramyxovirus in some specimens, but the focus has shifted almost exclusively to the coronavirus.
"Coronavirus is clearly a factor in this, and it may be just as simple as it appeared," Jahrling said.
"But maybe not."
Scientists in Canada have found the coronavirus in only 40 percent of the samples taken from probable SARS patients.
Dr. Frank Plummer, scientific director of Canada's National Microbiology Laboratory in Winnipeg, Manitoba, conceded that researchers could be looking in the wrong place -- in specimens taken from the nasal passage.
They could also be overdiagnosing SARS patients, meaning that those suspected of having the disease actually have another respiratory illness.
Even so, Plummer said last week that the link between SARS and the coronavirus is not yet clear.
'A fuzzy target'
If researchers do find an effective treatment, the virus could learn to outsmart it.
One strain of tuberculosis, dubbed multiple drug-resistant TB, can no longer be killed by traditional TB drugs, making it much more dangerous.
"It's a fuzzy target," said Jahrling, a top government virologist and one of the few scientists who have worked with smallpox in recent years.
But, he added, "It's infinitely better to have something than nothing. You use it until you find it's ineffective."
Scientists at Fort Detrick hope they will learn more about the virus from the animal experiment launched Friday.
Wearing battery-powered respirators and impermeable Tyvek suits in a "Biosafety Level 3" lab -- the second-highest level of danger -- they infected two sedated monkeys by dropping virus particles into their noses and sticking a bronchoscope into their lungs.
The third monkey was infected intravenously.
The monkeys, who could become ill within several days, have chest implants that will allow researchers to monitor their heart rate, blood pressure temperature and other signs. Chest X-rays will be taken every other day, along with measurements of blood oxygen levels.
The goal, in part, is to learn more about the way the virus works.
If any of the monkeys die, re-
searchers want to figure out whether it was simply because the virus attacked and shut down tissue cells or because their bodies launched an overzealous effort to fight it off.
They may also use infected monkeys in the future to test promising drugs or vaccines
Jahrling, for one, thinks SARS is here to stay -- much like the flu. "I'm moderately optimistic that we'll find something that has some efficacy" against it, he said.
But that doesn't mean it will be ready or appropriate for use in patients soon.
"That's going to be more of a challenge," he said.
Interferon the only drug that helps in SARS
http://www.sunspot.net/news/health/bal-te.lab27apr27,0,2963979.story?coll=bal-health-headlines
At Fort Detrick, a race to treat SARS
Skilled in deadly agents, Army experts test drugs to control the new virus
--------------------------------------------------------------------------------
Also see
Related Articles
China closes venues to halt SARS spread
Apr 27, 2003
Outbreak a heavy strain on China tourism
Authorities shorten May Day observance
Apr 27, 2003
China's live-animal markets part of agency's SARS investigation
Vendors may have role in first reported illness
Apr 27, 2003
Beijing orders theaters closed as SARS cases surge to 1,000
Health minister blamed for bungling outbreak resigns amid criticism
Apr 27, 2003
In Depth
SARS outbreak
Video
SARS symptoms (61K; KRT) (QuickTime plug-in required)
SARS virus (57K; KRT) (QuickTime plug-in required)
SARS travel (47K; KRT) (QuickTime plug-in required)
Photo Gallery
SARS outbreak
On The Web
Warning from the Centers for Disease Control and Prevention
WHO: Cases by country
Related Articles
SARS questions and answers
In Depth
Medicine & Science coverage
New coverage from The Sun.
Related Articles
Seminars and events
Top Stories
Mapping out a plan for getting exercise on the road
Fitness Q&A
Finding the man behind the muscle
His physique graces magazines, novels
In Mosul, attention turns toward needs of hospital
But Iraqi doctors wary of U.S. medical officers
Kolata on fitness:
13 more die of SARS in Asia
Thousands quarantined; fatalities reach Philippines; Strict new measures in effect
By Erika Niedowski
Sun Staff
Originally published April 27, 2003
FREDERICK -- A few weeks ago their world was all bioterror. They were fighting smallpox and other infectious diseases that could threaten U.S. troops.
Today, the Army's top scientists may also be the best hope in the fight against an enemy that no one expected -- the deadly virus responsible for SARS.
"When the fire bell rings, you go down the pole. It's the right thing. It's a clear public health emergency," says Peter B. Jahrling, principal scientific adviser at the U.S. Army Medical Research Institute for Infectious Diseases.
In sealed labs in nondescript buildings, scientists on the grounds of Fort Detrick are used to handling the most dangerous agents. They routinely work with the Ebola virus wearing full-body biohazard suits. Two years ago, they opened an anthrax-laced letter mailed to a U.S. senator and conducted sophisticated tests on the powder inside.
Now, researchers at this heavily guarded base near the Catoctin Mountains are testing more than 2,000 drugs that might be effective against severe acute respiratory syndrome. The aggressive virus has sickened more than 4,600 people and killed at least 276 worldwide since November.
On Friday, the Fort Detrick scientists infected three monkeys with the SARS virus in hopes that it will help them learn more about how it attacks the body.
Normally, they study the potential threat to U.S. troops from disease and biowarfare. Jahrling said it was a "hard sell" to convince some of them a few weeks ago how important it was to shift gears, particularly in the middle of the war in Iraq.
"It's a bit of a balancing act," he said. "We are probably the best-equipped lab to get these answers in short order."
Scientists here have screened about 125 compounds since receiving a plastic foam box containing samples of the SARS virus from the Centers for Disease Control and Prevention last month.
"We're not trying to be too clever, because we don't know enough about the virus to be too clever," said John W. Huggins, chief of viral therapeutics in the institute's virology division and head of the 20-member SARS team.
Already, they have determined that one leading drug, ribavirin, used in combination with steroids on SARS patients in Toronto and Hong Kong, is not effective.
The only drug that has stopped the new coronavirus from replicating is interferon. But scientists fear that the dose required is too toxic to be safe.
Screening 800 drugs
In all, Fort Detrick will be screening more than 800 drugs on the market, including 40 anti-virals used to treat AIDS, herpes, hepatitis and influenza. Finding an effective treatment among that group would be the best-case scenario because the drug could be used immediately.
But none seems promising so far.
Scientists are planning to test at least another 1,500 drugs that are under development in laboratories.
The National Institute of Allergy and Infectious Diseases in Bethesda has been gathering them, primarily from pharmaceutical companies, and sending them to Fort Detrick.
Huggins believes that at best, researchers will find an existing drug that "sort of works." But in the end, he says, it may be necessary to develop an altogether new one.
At least one drug firm, AVI BioPharma of Portland, Ore., has been collaborating with outside labs to do just that. The company, which has worked with animal coronaviruses in the past, plans to send its new compound to the National Institutes of Health for further testing, a spokeswoman said.
Viruses are harder to defeat than bacteria, in part because they frequently mutate. The new virus believed to be behind the SARS outbreak consists of a single strand of RNA, which can make mistakes as it replicates.
"RNA viruses are, by their nature, very easily mutated," Jahrling explained.
Another culprit?
They may also recombine with other viruses. Jahrling thinks that scientists world-wide have been too quick to discount the possibility of a co-infection -- the coronavirus operating in concert with another agent.
Early on in the outbreak, researchers isolated a paramyxovirus in some specimens, but the focus has shifted almost exclusively to the coronavirus.
"Coronavirus is clearly a factor in this, and it may be just as simple as it appeared," Jahrling said.
"But maybe not."
Scientists in Canada have found the coronavirus in only 40 percent of the samples taken from probable SARS patients.
Dr. Frank Plummer, scientific director of Canada's National Microbiology Laboratory in Winnipeg, Manitoba, conceded that researchers could be looking in the wrong place -- in specimens taken from the nasal passage.
They could also be overdiagnosing SARS patients, meaning that those suspected of having the disease actually have another respiratory illness.
Even so, Plummer said last week that the link between SARS and the coronavirus is not yet clear.
'A fuzzy target'
If researchers do find an effective treatment, the virus could learn to outsmart it.
One strain of tuberculosis, dubbed multiple drug-resistant TB, can no longer be killed by traditional TB drugs, making it much more dangerous.
"It's a fuzzy target," said Jahrling, a top government virologist and one of the few scientists who have worked with smallpox in recent years.
But, he added, "It's infinitely better to have something than nothing. You use it until you find it's ineffective."
Scientists at Fort Detrick hope they will learn more about the virus from the animal experiment launched Friday.
Wearing battery-powered respirators and impermeable Tyvek suits in a "Biosafety Level 3" lab -- the second-highest level of danger -- they infected two sedated monkeys by dropping virus particles into their noses and sticking a bronchoscope into their lungs.
The third monkey was infected intravenously.
The monkeys, who could become ill within several days, have chest implants that will allow researchers to monitor their heart rate, blood pressure temperature and other signs. Chest X-rays will be taken every other day, along with measurements of blood oxygen levels.
The goal, in part, is to learn more about the way the virus works.
If any of the monkeys die, re-
searchers want to figure out whether it was simply because the virus attacked and shut down tissue cells or because their bodies launched an overzealous effort to fight it off.
They may also use infected monkeys in the future to test promising drugs or vaccines
Jahrling, for one, thinks SARS is here to stay -- much like the flu. "I'm moderately optimistic that we'll find something that has some efficacy" against it, he said.
But that doesn't mean it will be ready or appropriate for use in patients soon.
"That's going to be more of a challenge," he said.
The only drug that has stopped the new coronavirus from replicating is interferon. But scientists fear that the dose required is too toxic to be safe.
The only drug that has stopped the new coronavirus from replicating is interferon. But scientists fear that the dose required is too toxic to be safe.
Scientists here have screened about 125 compounds since receiving a plastic foam box containing samples of the SARS virus from the Centers for Disease Control and Prevention last month.
"We're not trying to be too clever, because we don't know enough about the virus to be too clever," said John W. Huggins, chief of viral therapeutics in the institute's virology division and head of the 20-member SARS team.
Already, they have determined that one leading drug, ribavirin, used in combination with steroids on SARS patients in Toronto and Hong Kong, is not effective.
The only drug that has stopped the new coronavirus from replicating is interferon. But scientists fear that the dose required is too toxic to be safe.
Scientists here have screened about 125 compounds since receiving a plastic foam box containing samples of the SARS virus from the Centers for Disease Control and Prevention last month.
"We're not trying to be too clever, because we don't know enough about the virus to be too clever," said John W. Huggins, chief of viral therapeutics in the institute's virology division and head of the 20-member SARS team.
Already, they have determined that one leading drug, ribavirin, used in combination with steroids on SARS patients in Toronto and Hong Kong, is not effective.
The only drug that has stopped the new coronavirus from replicating is interferon. But scientists fear that the dose required is too toxic to be safe.
Stockwatch News Item
Southwestern Resources Corp (C-SWG) - In the News
Casey's van Eeden says sell Southwestern
Southwestern Resources Corp SWG
Shares issued 16,459,000 Apr 25 2003 close $ 13.28
Friday April 25 2003 In the News
Paul van Eeden, writing in the March 4 issue of Doug Casey's International Speculator, says Southwestern Gold is a sell at $14.55 because the geological reality of its Boka project in Yunnan does not match its lofty valuation. Mr. Casey recommended the stock in March, 2002, at $2.98. Earlier tips were May, 1996, at $15.87, and again in June, 1996, at $20. It peaked at $27.05 in May, 1996. In January this year at $12.40, soon after the Boka discovery, Mr. van Eeden suggested investors "keep an eye" on Southwestern, while at the same time cautioning there may be zones of weak mineralization. In the current issue, Mr. van Eeden says his earlier caution was justified. On March 7, the company released results from DH-1 showing what were apparently good weighted average grades. The market interpreted the results as excellent. Mr. van Eeden disagrees, suspecting that 55 metres for which assay results were not reported comprised very narrow high-grade zones in what was otherwise low-grade, or essentially unmineralized, material. SWG's relatively high market cap may reflect optimism that future results will indicate the high-grade zone has significant size potential, but this is hardly a sure thing.
(c) Copyright 2003 Canjex Publishing Ltd. http://www.stockwatch.com
old url (better for printing)
GenVec, Medarex to tackle SARS old news
I don't keep it up you do.So be it then.
Just because I posted to EC Bookmark on SI you get me banned for 30 Days(No big Deal)so tell me who keeps it up?
You wrote it and accused me its right there in black and white.
http://www.investorshub.com/boards/read_msg.asp?message_id=953650
You just accused me of having Multiple ID's here and SI as well.
So lets see Marcos What the result is from Matt.
http://www.investorshub.com/boards/read_msg.asp?message_id=953650
There you go its done
Via Message was sent to Matt in form of PM
Hello IH Admin{Matt}
Could you please put this to rest and check my IP Address and see if I have Multiple ID's Here.
Please post your findings to MARCOS in Public
Thankyou
_______________________________________________________________
_The Lounge / The Sheriff's Office / The Parking Lot
Public Reply / Private Reply / Keep / Mark Last Read Replies (1) / Next 10 / Previous / Next
Posted by: marcos
In reply to: Phil (Bullrider) who wrote msg# 2378 Date:4/26/2003 3:45:58 PM
Post #of 2384
It's a metaphorical 'to short' in use here, i think .... example, in this post Red claims to have covered his 'short' at 1.05 - #msg-909847 .... well the trading log for 9 april reveals a grand total of 600 shares traded at that price -g- .... coulda been the nominally symbolic 'to short', i guess eh -g-
Irony to the whole thing, is that the poster i was defending back then now has an active thread here on ihub, and Red posts on it with apparent amiability, while the worst examples of his multiple login allies have been run out of here some time ago [and out of SI as well i think, not sure but i don't see 'them' around] .... go figure eh .... well we'll see if he wants peace now ... cheers
______________________________________________________________
The Lounge / The Sheriff's Office / The Parking Lot
Public Reply / Private Reply / Keep / Mark Last Read Replies (1) / Next 10 / Previous / Next
Posted by: Rocketred
In reply to: marcos who wrote msg# 2381 Date:4/26/2003 3:59:09 PM
Post #of 2384
while the worst examples of his multiple login allies have been run out of here some time ago [and out of SI as well i think, not sure but i don't see 'them' around] .... go figure eh .... well we'll see if he wants peace now ... cheers
_______________________________________________________________
See there you go again Accusing me of having Multiple login allies.
LOL
Your IP ADDRESS is a dead give away.
get MATT to check if I ever had Allies here that will put a rest on this bs you like to spread around.
send this message to Matt with my permission to do all the checking he likes.
Then come back here and post I have Multiple ID's
I would expect this will be the last word I here from you on this.
Marcos I gave you full permission to check with I-Hub
Do so to please yourself.
Send that message to I-hub Or better yet mabye I should just ask MATT to check myself and let him respond to this thread.
Your full of BS marcos and you know very well this will Prove your wrong.
Is your ego that big??????
while the worst examples of his multiple login allies have been run out of here some time ago [and out of SI as well i think, not sure but i don't see 'them' around] .... go figure eh .... well we'll see if he wants peace now ... cheers
_______________________________________________________________
See there you go again Accusing me of having Multiple login allies.
LOL
Your IP ADDRESS is a dead give away.
get MATT to check if I ever had Allies here that will put a rest on this bs you like to spread around.
send this message to Matt with my permission to do all the checking he likes.
Then come back here and post I have Multiple ID's
I would expect this will be the last word I here from you on this.
April 28, 2003 / Vol. 161 No. 16
Health
Why Viruses are Hard to Kill
The latest SARS science
BY BRYAN WALSH / HONG KONG
Regional Affair: Beijing waffles as SARS strikes the interior
Essay: Where the scrubbing never stops
Cover-up: Silent for too long
MORE STORIES
Shanghai SARS Cases 'Secret'
Viruses: Hard to Kill
Hong Kong: Keep on Scrubbing
China: SARS Hits the Hinterland
Coverup: Silent for Too Long
Beijing Hoodwinks WHO Inspectors
Stalking a Killer
What are Superspreaders?
Unmasking a Crisis
PHOTOS & GRAPHICS
On Assignment: The SARS Outbreak
How the Virus Spreads
How a Coronavirus Works
How to Protect Yourself
Dr. Julie Gerberding, director of the U.S. Centers for Disease Control and Prevention, was elated. In a matter of weeks--not months or years--teams of scientists whose work was coordinated by the World Health Organization had managed to decode the entire genetic sequence of the new coronavirus now conclusively believed to cause SARS, or severe acute respiratory syndrome. "It's a scientific achievement that I don't think has ever been paralleled in human history," said Dr. Gerberding shortly before the April 16 announcement that the coronavirus's genetic fingerprint had been fully identified.
Theoretically, the achievement should lead to better diagnostic tools, treatments and perhaps even a vaccine for SARS. Germany's Artus Biotech has already released what it claims is a highly accurate test kit that can detect SARS in less than three hours. But as has been shown in AIDS research, knowing your enemy is merely the first battle in what is likely to be a lengthy war. AIDS and SARS (and the common cold, for that matter) are caused by viruses--and viruses are notoriously hard to kill. Although doctors have a huge arsenal of drugs and antibiotics capable of wiping out most bacterial infections, a viral invasion is a tougher proposition. "All along, it's been much easier to produce agents to kill bacteria than to kill viruses," says Professor Brian Tomlinson, a clinical pharmacologist at the Chinese University of Hong Kong (CUHK).
The reason lies in the nature of the pathogens themselves. Bacteria are living organisms that, multiplying unchecked, damage bodily tissue. They can be destroyed by cutting off their life-support systems. Antibiotics defeat bacterial infections by attacking enzymes within the bacteria, allowing the body's immune system to mop them up. Viruses, however, are parasites incapable of reproducing on their own. They're inactive--that is, until they burrow into a host cell, taking over its functions in order to replicate and thereby destroying the host. Inside the body, they become vulnerable to drugs only after they invade a cell, but any treatment may damage the cell as well. And even when scientists develop an effective vaccine or antiviral agent, viruses can suddenly mutate--potentially becoming deadlier and even tougher to eliminate.
A virus's worst enemy is the human immune system. When an unknown pathogen like the new coronavirus invades, the body naturally develops antibodies that can seek out and destroy the interloper. The process takes time, however, and sometimes the system doesn't react fast enough. Science can help with vaccines, which prep the body to recognize and produce antibodies against a particular attacker, such as polio. A vaccine for SARS is under development, but even the most optimistic researchers say it may take more than a year to come up with one that works.
In the meantime, clinicians are working feverishly to fine-tune existing antiviral drugs and treatments in order to render SARS less deadly. At present, about one in every 20 SARS victims dies, usually due to swelling in the lungs, a result of the body's own immune-system response. In Hong Kong, doctors claim they are successfully combating the disease using the antiviral drug ribavirin to inhibit the virus combined with corticosteroids to check an overstimulated immune response. Ribavirin works by interfering with intracellular viral replication, slowing the infection's spread within the body. The problem, as microbiologist Professor John Tam of CUHK points out, is that "if you stop the replication, that means you stop the function of the cell."
Ribavirin's side effects, which include anemia, become dangerous at prolonged high dosages. Moreover, laboratory tests in the U.S. suggest that ribavirin may actually do nothing to the coronavirus. Scientists are exploring other antivirals--such as interferon, which boosts the immune system--or even HIV drugs--such as protease inhibitors, which block an enzyme the virus needs to replicate. But too little is known about the coronavirus to predict the effectiveness of these other drugs.
Researchers are even more worried that the coronavirus, which may be a mutated version of a virus common to animals, could mutate again, becoming more resistant to current treatments. "We are beginning to see patients not responding," says Tam, "and that's a very worrying development." A shape shift in the coronavirus' genetic code can make it more virulent and contagious. Highly mutable HIV continues to frustrate doctors, as it transforms before a vaccine can be developed.
Fortunately, the coronavirus seems to be more stable than HIV, and researchers are confident that SARS-specific antivirals and vaccines can be developed over time. For those patients already under attack from a microbe science is only beginning to understand, that help may be too little, too late.
Billion SARS cases feared
By Mary Papadakis
April 27, 2003
MORE than one billion people worldwide could be infected by the deadly SARS virus within a year, a leading UK scientist has warned.
Dr Patrick Dixon, a specialist in predicting global trends based at London's Development Management School, said SARS (Severe Acute Respiratory Syndrome) had the potential to turn into a pandemic and infect more people than AIDS.
The grim prediction comes as a Melbourne infection control specialist warned the virus could destroy Third World countries.
Glenys Harrington, who flew to Manila yesterday to join the World Health Organization's assault on SARS, said the virus was a major threat to developing nations.
"Countries that are Third World or very poor may in fact be easily overwhelmed by SARS," she said.
Dr. Susan Lai, a coronavirus expert at the University of Beijing, said spraying interferon through the nasal passages blocks infection in similar coronaviruses' which is the cause of the common cold and SARS "the difference, SARS is a worldwide assassin while the common-cold is a global inconvenience. Among the leading promising drugs initially tested, interferon alpha is especially interesting" Lai said.
From the VRA home page, see the enclosed link and scroll down to; Company Website.
What is Multiferon™?
Multiferon is a highly purified, multi-subtype, natural human alpha interferon derived from human white blood cells, a central component of the body's immune system.
http://biz.yahoo.com/p/v/vra.html
Dr. Susan Lai, a coronavirus expert at the University of Beijing, said spraying interferon through the nasal passages blocks infection in similar coronaviruses' which is the cause of the common cold and SARS "the difference, SARS is a worldwide assassin while the common-cold is a global inconvenience. Among the leading promising drugs initially tested, interferon alpha is especially interesting" Lai said.
From the VRA home page, see the enclosed link and scroll down to; Company Website.
What is Multiferon™?
Multiferon is a highly purified, multi-subtype, natural human alpha interferon derived from human white blood cells, a central component of the body's immune system.
http://biz.yahoo.com/p/v/vra.html
Dr. Susan Lai, a coronavirus expert at the University of Beijing, said spraying interferon through the nasal passages blocks infection in similar coronaviruses' which is the cause of the common cold and SARS "the difference, SARS is a worldwide assassin while the common-cold is a global inconvenience. Among the leading promising drugs initially tested, interferon alpha is especially interesting" Lai said.
From the VRA home page, see the enclosed link and scroll down to; Company Website.
What is Multiferon™?
Multiferon is a highly purified, multi-subtype, natural human alpha interferon derived from human white blood cells, a central component of the body's immune system.
http://biz.yahoo.com/p/v/vra.html
Somebody make this up or is this coming out monday?????
by: in2it_411 (47/M/NYC)
Long-Term Sentiment: Strong Buy 04/25/03 05:54 pm
Msg: 70240 of 70456
only one that I've come across [and my source is pretty good];
PLANTATION, Fla., April 28, 2003 09:07:00 AM ET /PRNewswire-FirstCall/ Viragen Inc. [VRA] began development last week of a clinical interferon grade vaccine against Severe Acute Respiratory Syndrome (SARS) using their natural interferon program technology...
more to follow!
in2it
Somebody make this up or is this coming out monday?????
by: in2it_411 (47/M/NYC)
Long-Term Sentiment: Strong Buy 04/25/03 05:54 pm
Msg: 70240 of 70456
only one that I've come across [and my source is pretty good];
PLANTATION, Fla., April 28, 2003 09:07:00 AM ET /PRNewswire-FirstCall/ Viragen Inc. [VRA] began development last week of a clinical interferon grade vaccine against Severe Acute Respiratory Syndrome (SARS) using their natural interferon program technology...
more to follow!
in2it
Somebody make this up or is this coming out monday?????
by: in2it_411 (47/M/NYC)
Long-Term Sentiment: Strong Buy 04/25/03 05:54 pm
Msg: 70240 of 70456
only one that I've come across [and my source is pretty good];
PLANTATION, Fla., April 28, 2003 09:07:00 AM ET /PRNewswire-FirstCall/ Viragen Inc. [VRA] began development last week of a clinical interferon grade vaccine against Severe Acute Respiratory Syndrome (SARS) using their natural interferon program technology...
more to follow!
in2it
Viragen, symbol VRA, that makes a drug called Alpha Interferon.
"Among the promising drugs that have been tested, interferon alpha is especially interesting, the director of the National Institute of Allergies and Infectious Diseases told members of Congress a week ago. An interferon alpha nasal spray was shown to be effective during research in the 1980's against colds caused by the coronavirus, but the research was abandoned because of excessive irritation. But in the face of SARS, the side effects could become acceptable."
Viragen, symbol VRA, that makes a drug called Alpha Interferon.
"Among the promising drugs that have been tested, interferon alpha is especially interesting, the director of the National Institute of Allergies and Infectious Diseases told members of Congress a week ago. An interferon alpha nasal spray was shown to be effective during research in the 1980's against colds caused by the coronavirus, but the research was abandoned because of excessive irritation. But in the face of SARS, the side effects could become acceptable."
Viragen, symbol VRA, that makes a drug called Alpha Interferon.
"Among the promising drugs that have been tested, interferon alpha is especially interesting, the director of the National Institute of Allergies and Infectious Diseases told members of Congress a week ago. An interferon alpha nasal spray was shown to be effective during research in the 1980's against colds caused by the coronavirus, but the research was abandoned because of excessive irritation. But in the face of SARS, the side effects could become acceptable."
http://cooltech.iafrica.com/science/229961.htm
Link for VRA-50 million shares traded friday
GNVC Another Hot SARS stock today
AVII was another hot one today